Scoop: Boehringer qui­et­ly shut­ters a PhII for one of its top drugs — now un­der re­view

Boehringer In­gel­heim has qui­et­ly shut down a small Phase II study for one of its lead drugs.

The pri­vate phar­ma play­er con­firmed to End­points News …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.